Novel agents in hodgkin lymphoma Journal Article
| Author: | Moskowitz, A. J. |
| Article Title: | Novel agents in hodgkin lymphoma |
| Abstract: | Despite the success of modern therapy for Hodgkin lymphoma (HL), about 15 % of patients will fail both first-line and second-line therapy and treatment options for these patients are limited. New agents are needed to improve the outcome for relapsed or refractory HL and to improve the toxicity of current front-line regimens. Brentuximab vedotin (BV) was recently approved for HL and is likely to have a tremendous impact on the current treatment paradigm for HL. Additional agents that have demonstrated activity in HL include histone deacetylase inhibitors, such as panobinostat, entinostat, and mocetinostat, PI3-kinase/ Akt/Mtor pathway inhibitors, such as everolimus, as well as lenalidomide and bendamustine. Studies evaluating these agents alone or in combination with either chemotherapy or other targeted agents are ongoing. Current challenges in HL research include identifying the most appropriate drug combinations of new and old drugs and identifying predictors of response to the new targeted agents. © Springer Science+Business Media, LLC 2012. |
| Keywords: | treatment outcome; treatment response; histone deacetylase inhibitor; lenalidomide; thalidomide; drug tolerability; fatigue; neutropenia; cancer recurrence; cisplatin; doxorubicin; diarrhea; drug dose comparison; drug dose reduction; drug efficacy; drug potentiation; drug safety; treatment duration; antineoplastic agents; drug approval; cytarabine; antineoplastic agent; medical decision making; dacarbazine; progression free survival; drug eruption; multiple cycle treatment; sensory neuropathy; anemia; lung disease; nausea; thrombocytopenia; peripheral neuropathy; bendamustine; dexamethasone; autologous stem cell transplantation; antineoplastic activity; cancer research; prediction; vinblastine; hodgkin disease; temsirolimus; protein kinase inhibitors; acute graft versus host disease; chronic graft versus host disease; reduced intensity conditioning; vorinostat; histone deacetylase inhibitors; bleomycin; progressive multifocal leukoencephalopathy; drug treatment failure; pericardial effusion; everolimus; panobinostat; sirolimus; hematologic disease; nitrogen mustard compounds; hodgkin lymphoma; stevens johnson syndrome; motor neuropathy; phosphatidylinositol 3 kinase inhibitor; thymus and activation regulated chemokine; mocetinostat; phase 2 clinical trial (topic); phase 3 clinical trial (topic); immunoconjugates; entinostat; hdac inhibitors; brentuximab vedotin; sgn-35; cal-101; panobinostat .mtorinhibitors; idelalisib |
| Journal Title: | Current Oncology Reports |
| Volume: | 14 |
| Issue: | 5 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2012-10-01 |
| Start Page: | 419 |
| End Page: | 423 |
| Language: | English |
| DOI: | 10.1007/s11912-012-0251-y |
| PROVIDER: | scopus |
| PUBMED: | 22706966 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "CODEN: CORUA" - "Source: Scopus" |
